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The recent introduction of faecal transplants will help to
enrich the therapeutic arsenal, and poses questions about their
indications and their implementation. Faecal transplantation is
not a medicine but a therapeutic strategy, for which the
legislative framework can be difﬁcult to determine. We have
here an article by Lagier [1], who tries to determine what the
problems are and what could be the industrial solutions to
facilitate management. Indeed, currently, evaluation of the risk
of transmissibility from donors and the ad hoc preparation of
each faecal transplant are undoubtedly obstacles to the regular
use of faecal transplantation. Moreover, indications for faecal
transplantation will certainly evolve; an initial study has shown
efﬁcacy in patients with Clostridium difﬁcile infections resistant
to standard therapies [2,3].
However, the practical implementation of faecal transplan-
tion poses many problems, as there is an increasing demand,
owing to the recognition of increasingly common colitis caused
by C. difﬁcile. C. difﬁcile O27 appears to have greater virulence
than other strains, and although its incidence is declining in
certain geographical areas in Europe, its incidence seems to be
growing in other areas, including France [4]. All in all,
considering the fact that the mortality resulting from C. difﬁcile
is estimated at 30 000 annual deaths in Europe and in the USA,
the development of new strategies is a key priority [5]. Early
faecal transplantation has been shown to be cost-effective [6].
The different strategies that can be implemented may lead to
the need for a national consensus, and the Austrian experience
reported here gives an example of the organization that is
necessary to respond to this unusual problem [3]. Finally,
other indications have emerged besides C. difﬁcile colitis,
especially for the eradication of multiresistant bacteria [7,8].
Besides removal from the digestive tract of microorganisms
that are involved in disease or that may pose problems of
transmission of multidrug resistance, many other indications
have been proposed for some nutrition problems, with
experimental models showing interest regarding the ﬁght
against obesity or malnutrition, and solutions that have not yet
been validated for the treatment of chronic colic infections.
In total, we are experiencing the emergence of a new
therapeutic strategy for replacing the gastrointestinal microb-
iome. Different routes can be used, such as ﬁbroscopy through
duodenal injection, colonic inoculation, or nasogastric tubes
[9]. Not many indications have yet been validated, but the
development of completely new therapeutic strategies of this
nature shows us that the list of our therapies will still evolve,
sometimes in a totally unexpected way.
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